Details for Patent: 9,382,200

Title:	Process for the preparation of and crystalline forms of optical enantiomers of modafinil
Abstract:	The invention relates to a polymorphic form of (-)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 8.54, 4.56, and 3.78 .ANG., and a process for the preparation thereof.
Inventor(s):	Neckebrock; Olivier (Pontault Combault, FR), Courvoisier; Laurent (Laigneville, FR), Graf; Stephanie (Belloy En France, FR), Serrure; Gilles (Vernouillet, FR), Coquerel; Gerard Francois (Boos, FR), Rose; Sebastien (Arsy, FR), Besselievre; Christine (Bures sur Yvette, FR), Mallet; Franck Patrick (Blangy sur Bresle, FR), Van Langevelde; Adriaan Jan (Almere, NL)
Assignee:	Teva Sante (La Defense (Paris), FR)
Filing Date:	Jul 22, 2009
Application Number:	12/507,584
Claims:	1. A polymorphic form of (-)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 8.54, 4.56, and 3.78 .ANG.. 2. The polymorphic form according to claim 1, wherein the powder X-ray diffraction spectrum further comprises intensity peaks corresponding to interplanar spacings of about 7.57, 7.44, and 3.71 .ANG.. 3. A polymorphic form of (-)-modafinil that produces a powder X-ray diffraction spectrum comprising reflections at about 15.4, 29.1 and 35.3 degrees 2.theta.. 4. The polymorphic form according to claim 3, wherein the powder X-ray diffraction spectrum further comprises reflections at about 17.4, 17.7 and 35.9 degrees 2.theta.. 5. A composition consisting essentially of a polymorphic form of (-)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 8.54, 4.56, and 3.78 .ANG.. 6. The composition according to claim 5, wherein the powder X-ray diffraction spectrum further comprising intensity peaks corresponding to interplanar spacings of about 7.57, 7.44, and 3.71 .ANG.. 7. A composition consisting essentially of a polymorphic form of (-)-modafinil that produces a powder X-ray diffraction spectrum comprising reflections at about 15.4, 29.1 and 35.3 degrees 2.theta.. 8. The composition according to claim 7, wherein the powder X-ray diffraction spectrum further comprising reflections at about 17.4, 17.7 and 35.9 degrees 2.theta.. 9. A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a polymorphic form of (-)-modafinil as defined in claim 1. 10. A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a polymorphic form of (-)-modafinil as defined in claim 2. 11. A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a polymorphic form of (-)-modafinil as defined in claim 3. 12. A pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a polymorphic form of (-)-modafinil as defined in claim 4. 13. A process for preparing the polymorph of (-)-modafinil of claim 1, comprising the steps of: (a) providing a solution of (-)-modafinil dissolved in a hot solvent; (b) cooling the solution from step (a) to produce crystals; (c) filtering the crystals; (d) drying the crystals; and (e) obtaining the crystals of said polymorph of (-)-modafinil, wherein the solvent of step (a) is selected from isopropanol, ethyl acetate, n-propanol, and ethanol denatured with toluene, and wherein the obtained crystals are substantially free of Form I (-)-modafinil. 14. A process for preparing the polymorph of (-)-modafinil of claim 1, comprising the steps of: (a) providing a solution of (-)-modafinil dissolved in a hot solvent; (b) cooling the solution from step (a) to produce crystals; (c) filtering the crystals; (d) drying the crystals; and (e) obtaining the crystals of said polymorph of (-)-modafinil, wherein the solvent of step (a) is selected from isopropanol, ethyl acetate, n-propanol, and ethanol denatured with toluene, and wherein the obtained crystals are substantially free of Form IV (-)-modafinil. 15. A process for preparing the polymorph of (-)-modafinil of claim 1, comprising the steps of: (a) providing a solution of (-)-modafinil dissolved in a hot solvent; (b) cooling the solution from step (a) to produce crystals; (c) filtering the crystals; (d) drying the crystals; and (e) obtaining the crystals of said polymorph of (-)-modafinil, wherein the solvent of step (a) is selected from isopropanol, ethyl acetate, n-propanol, and ethanol denatured with toluene, and wherein the obtained crystals are substantially free of Form V (-)-modafinil. 16. A process for preparing the polymorph of (-)-modafinil of claim 1, comprising the steps of: (a) providing a solution of (-)-modafinil dissolved in a hot solvent; (b) cooling the solution from step (a) to produce crystals; (c) filtering the crystals; (d) drying the crystals; and (e) obtaining the crystals of said polymorph of (-)-modafinil, wherein the solvent of step (a) is selected from isopropanol, ethyl acetate, n-propanol, and ethanol denatured with toluene, and wherein the obtained crystals are substantially free of Forms I, IV and V (-)-modafinil. 17. A process for preparing the polymorph of (-)-modafinil of claim 1, comprising the steps of: (a) providing a solution of (-)-modafinil dissolved in a hot solvent; (b) cooling the solution from step (a) to produce crystals; (c) filtering the crystals; (d) drying the crystals; and (e) obtaining the crystals of said polymorph of (-)-modafinil, wherein the solvent of step (a) is selected from isopropanol, ethyl acetate, n-propanol, and ethanol denatured with toluene, and wherein the obtained crystals are substantially free of other polymorphic forms of (-)-modafinil. 18. A process for preparing the polymorph of (-)-modafinil of claim 1, comprising the steps of: (a) providing a solution of (-)-modafinil dissolved in a hot solvent; (b) cooling the solution from step (a) to produce crystals; (c) filtering the crystals; (d) drying the crystals; and (e) obtaining the crystals of said polymorph of (-)-modafinil, wherein the solvent of step (a) is selected from isopropanol, ethyl acetate, n-propanol, and ethanol denatured with toluene.